<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739971</url>
  </required_header>
  <id_info>
    <org_study_id>AGEs-brain</org_study_id>
    <nct_id>NCT02739971</nct_id>
  </id_info>
  <brief_title>Dietary Reduction of AGEs to Prevent Cognitive Decline in Elderly Diabetics</brief_title>
  <official_title>Dietary Reduction of Advanced Glycation End Products to Prevent Cognitive Decline in Elderly Diabetics - a Randomized Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basic science and observational human studies suggest that high conentrations of circulating
      Advanced Glycation End-products (AGEs) may promote cognitive decline in older adults. The
      purpose of this pilot study is to test the methodology and feasibility of a dietary
      intervention to lower AGEs in elderly diabetics in order to lay the foundations for a future
      fully powered randomized clinical trial (RCT).To this end, the present study is focused on
      recruitment strategies, adherence to an innovative intervention in older adults and study
      methods. An exploratory aim will be the effect of the intervention on cognition and cerebral
      blood flow in order to obtain necessary data to estimate effect-size for a future
      fully-powered RCT.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized pilot trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The participants and study dietitian can not be blind to the assigned dietary intervention. However, the clinical testing and all data analysis are carried out blind to the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in AGEs markers in serum (carboxymethyl lysine, CML and Methylglyoxal ,MG ) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Blood draws before and at the end of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recruiting rate assessment</measure>
    <time_frame>2 years of total recruitment</time_frame>
    <description>calculate the eligible subjects from those attended screening visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retention rate to the diet</measure>
    <time_frame>6 months</time_frame>
    <description>to report the retention rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The influence of AGE reduction on cognition</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in cognition using a Z score of global and domain specific (language, attention, memory ) cognition following 6 months of AGEs reduction compared to standard of care (this is an exploratory aim since this is a pilot study)</description>
  </other_outcome>
  <other_outcome>
    <measure>The influence of AGE reduction on cerebral blood flow-measured with arterial spin labeling MRI (ASL-MRI)</measure>
    <time_frame>6 months</time_frame>
    <description>changes in cerebral blood flow measured with ASL MRI following 6 months of AGEs reduction compared to standard of care ( this is an exploratory aim since this is a pilot study)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in microbial diversity and composition of fecal microbiome following AGE reduction in diet</measure>
    <time_frame>6 months</time_frame>
    <description>microbiota composition will be analyzed (eg. the amount and relative proportions of major bacterial genus and species Bifidobacterium, Bacteroides, Lactobaillus, Enterobacteria, Eubacteria,etc. using 16S rRNA profiling ) before and after intervention of AGEs reduction and changes will compared to standard of care arm. This is a descriptive exploratory outcome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Aging</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Low AGEs diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care dietary guidance</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low AGEs diet</intervention_name>
    <description>Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes</description>
    <arm_group_label>Low AGEs diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of care dietary guidance for Type 2 diabetes</intervention_name>
    <description>Oral and written instructions for standard of care dietary guidance for type 2 diabetes</description>
    <arm_group_label>Low AGEs diet</arm_group_label>
    <arm_group_label>Standard of care dietary guidance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Above the age 65

          -  T2D diagnosis

          -  no dementia (i.e MCI or cognitively normal )

          -  Not receiving cholinesterase inhibitors

          -  No other neurological (e.g. stroke, Parkinson's disease) or psychiatric conditions
             (e.g. schizophrenia, depression) that may affect cognition

          -  Dietary AGE levels &gt; 13kU

          -  Not participating in another clinical trial

          -  An informant that is willing to actively support the participant throughout the study

        Exclusion Criteria:

          -  Dementia

          -  Stroke

          -  Other major neuropsychiatric condition that might affect cognition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Schnaider Beeri, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Joseph Sagol Neuroscience Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aron M Troen, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew University of Jerusalem</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramit Ravona Springer, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Joseph Sagol Neuroscience Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joseph Sagol Neuroscience center, Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010 Jun;110(6):911-16.e12. doi: 10.1016/j.jada.2010.03.018.</citation>
    <PMID>20497781</PMID>
  </reference>
  <reference>
    <citation>Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, Woodward M, Striker GE, Vlassara H. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4940-5. doi: 10.1073/pnas.1316013111. Epub 2014 Feb 24.</citation>
    <PMID>24567379</PMID>
  </reference>
  <reference>
    <citation>Lubitz I, Ricny J, Atrakchi-Baranes D, Shemesh C, Kravitz E, Liraz-Zaltsman S, Maksin-Matveev A, Cooper I, Leibowitz A, Uribarri J, Schmeidler J, Cai W, Kristofikova Z, Ripova D, LeRoith D, Schnaider-Beeri M. High dietary advanced glycation end products are associated with poorer spatial learning and accelerated AÎ² deposition in an Alzheimer mouse model. Aging Cell. 2016 Apr;15(2):309-16. doi: 10.1111/acel.12436. Epub 2016 Jan 19.</citation>
    <PMID>26781037</PMID>
  </reference>
  <reference>
    <citation>Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011 Jul;34(7):1610-6. doi: 10.2337/dc11-0091.</citation>
    <PMID>21709297</PMID>
  </reference>
  <reference>
    <citation>Ravona-Springer R, Luo X, Schmeidler J, Wysocki M, Lesser G, Rapp M, Dahlman K, Grossman H, Haroutunian V, Schnaider Beeri M. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord. 2010;29(1):68-74. doi: 10.1159/000265552. Epub 2010 Jan 30.</citation>
    <PMID>20130405</PMID>
  </reference>
  <reference>
    <citation>Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007 Apr;64(4):570-5.</citation>
    <PMID>17420320</PMID>
  </reference>
  <reference>
    <citation>Beeri MS, Moshier E, Schmeidler J, Godbold J, Uribarri J, Reddy S, Sano M, Grossman HT, Cai W, Vlassara H, Silverman JM. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev. 2011 Nov-Dec;132(11-12):583-7. doi: 10.1016/j.mad.2011.10.007. Epub 2011 Nov 3.</citation>
    <PMID>22079406</PMID>
  </reference>
  <reference>
    <citation>West RK, Moshier E, Lubitz I, Schmeidler J, Godbold J, Cai W, Uribarri J, Vlassara H, Silverman JM, Beeri MS. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev. 2014 Sep;140:10-2. doi: 10.1016/j.mad.2014.07.001. Epub 2014 Jul 15.</citation>
    <PMID>25037023</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ramit Ravona Springer</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

